Atara Biotherapeutics Inc

NASDAQ:ATRAUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.

Contact Information

Headquarters

2380 Conejo Spectrum St, Suite 200THOUSAND OAKS, CA, United States 91320

Phone

805-623-4244

Fax

302-636-5454

Executives

Independent Chairman of the Board

Carol Gallagher

President, Chief Executive Officer, Director

Pascal Touchon

Chief Financial Officer, Executive Vice President

Eric Hyllengren

Executive Vice President, Chief Scientific and Technology Officer

Anhco Nguyen

Executive Vice President - Global Head Regulatory Affairs and Quality

Jill Henrich